By selecting the Yes, leave Amgen.com.hk option you understand that you are leaving the corporate page of Amgen Hong Kong and that you will be redirected to another Internet site belonging to third parties, for whose content or opinions Amgen Hong Kong is not responsible and makes no representations regarding such content or its accuracy. By selecting this option and accessing linked third party sites, you understand that you do so at your own risk.
The website to which you will be redirected may be designed exclusively for residents of a particular country or countries, as advertised on that website. As a consequence, the website to which you will be directed may contain information on pharmaceutical products or indications that are not approved in Hong Kong. If you reside in a country other than the one to which such website is directed, please contact your local Amgen affiliate for the correct information on products in your country of residence.
At Amgen Hong Kong, we provide innovative and high-quality treatments and biosimilar medicines in support of patients in Hong Kong and Macau in the following therapeutic areas:
In general medicine, Amgen is dedicated to addressing important scientific questions to advance care and improve the lives of patients with cardiovascular disease, the leading cause of morbidity and mortality worldwide.
In general medicine, Amgen is a leader in bone health with more than 20 years of osteoporosis research experience, and is committed to combating this disease to help people at high risk for fracture reduce their risk of a first and subsequent fracture.
Amgen has a portfolio of innovative products and biosimilars for the treatment of oncological and hematological diseases, such as colorectal cancer, leukemia and multiple myeloma.
Amgen developed medicines in the field of inflammation, and we are currently discovering innovative molecules to treat chronic inflammatory diseases. Some of the conditions to which we provide solutions are for autoimmune pathologies such as rheumatoid arthritis and psoriasis, which affect millions of patients in the world. Inflammation is another field in which Amgen has biosimilars approved to improve healthcare costs in chronic diseases.
For information on the drugs that are in development, we invite you to visit our pipeline.